<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83320</article-id><article-id pub-id-type="doi">10.7554/eLife.83320</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Syntaxin-6 delays prion protein fibril formation and prolongs presence of toxic aggregation intermediates</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-293753"><name><surname>Sangar</surname><given-names>Daljit</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-332066"><name><surname>Hill</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293754"><name><surname>Jack</surname><given-names>Kezia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293755"><name><surname>Batchelor</surname><given-names>Mark</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6847-5131</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293756"><name><surname>Mistry</surname><given-names>Beenaben</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-332067"><name><surname>Ribes</surname><given-names>Juan M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-332069"><name><surname>Jackson</surname><given-names>Graham S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-332068"><name><surname>Mead</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-292074"><name><surname>Bieschke</surname><given-names>Jan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3485-9767</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Institute of Prion Diseases</institution>, <institution>MRC Prion Unit</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-43262"><name><surname>Mapa</surname><given-names>Koyeli</given-names></name><role>Reviewing editor</role><aff><institution>Department of Life Sciences, School of Natural Sciences, Shiv Nadar University</institution>, <country>India</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>j.bieschke@ucl.ac.uk</email> (JB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>07</day><month>08</month><year>2024</year></pub-date><volume>13</volume><elocation-id>e83320</elocation-id><history><date date-type="received"><day>07</day><month>09</month><year>2022</year></date><date date-type="accepted"><day>20</day><month>07</month><year>2024</year></date></history><permissions><copyright-statement>Â© 2024, Sangar et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Sangar et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83320-v1.pdf"/><abstract><p>Prions replicate via the autocatalytic conversion of cellular prion protein (PrP<sup>C</sup>) into fibrillar assemblies of misfolded PrP. While this process has been extensively studied in vivo and in vitro, non-physiological reaction conditions of fibril formation in vitro have precluded the identification and mechanistic analysis of cellular proteins, which may alter PrP self-assembly and prion replication. Here, we have developed a fibril formation assay for recombinant murine and human PrP (23-231) under near-native conditions (NAA) to study the effect of cellular proteins, which may be risk factors or potential therapeutic targets in prion disease. Genetic screening suggests that variants that increase syntaxin-6 expression in the brain (gene: STX6) are risk factors for sporadic Creutzfeldt-Jakob disease (CJD). Analysis of the protein in NAA revealed, counterintuitively, that syntaxin-6 is a potent inhibitor of PrP fibril formation. It significantly delayed the lag phase of fibril formation at highly sub-stoichiometric molar ratios. However, when assessing toxicity of different aggregation time points to primary neurons, syntaxin-6 prolonged the presence of neurotoxic PrP species. Electron microscopy and super-resolution fluorescence microscopy revealed that, instead of highly ordered fibrils, in the presence of syntaxin-6 PrP formed less-ordered aggregates containing syntaxin-6. These data strongly suggest that the protein can directly alter the initial phase of PrP self-assembly and, uniquely, can act as an 'anti-chaperone', which promotes toxic aggregation intermediates by inhibiting fibril formation.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>1R21NS101588-01A1</award-id><principal-award-recipient><name><surname>Bieschke</surname><given-names>Jan</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MC_UU_00024/6</award-id><principal-award-recipient><name><surname>Sangar</surname><given-names>Daljit</given-names></name><name><surname>Batchelor</surname><given-names>Mark</given-names></name><name><surname>Jackson</surname><given-names>Graham S</given-names></name><name><surname>Bieschke</surname><given-names>Jan</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MRC Prion Unit Graduate Programme</award-id><principal-award-recipient><name><surname>Hill</surname><given-names>Elizabeth</given-names></name><name><surname>Jack</surname><given-names>Kezia</given-names></name><name><surname>Mistry</surname><given-names>Beenaben</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Work with animals was performed under the licence granted by the UK Home Office (Project Licences 70/6454 and 70/7274) and conformed to University College London institutional and ARRIVE guidelines.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study and all used analysis scripts have been uploaded to Mendeley data and are available to the public under doi: 10.17632/yggpkrgnx8.1</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Bieschke J</collab></person-group><year iso-8601-date="2024">2024</year><source>Syntaxin 6 delays prion protein fibril formation and prolongs presence of toxic aggregation intermediates</source><ext-link ext-link-type="uri" xlink:href="https://data.mendeley.com/datasets/yggpkrgnx8/1">https://data.mendeley.com/datasets/yggpkrgnx8/1</ext-link><comment>Mendeley Data, doi: 10.17632/yggpkrgnx8.1</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-83320-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>